Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats
Received 22 June 2019
Accepted for publication 21 October 2019
Published 21 November 2019 Volume 2019:13 Pages 3929—3937
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Professor Manfred Ogris
Nagla Ahmed El-Nabarawy,1 Mahmoud Hassan Teaima,2 Doaa Ahmed Helal3
1National Egyptian Center of Environmental & Toxicological Research (NECTR), Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Fayoum University, Elfayoum, Egypt
Correspondence: Nagla Ahmed El-Nabarawy
National Egyptian Center of Environmental & Toxicological Research (NECTR), Faculty of Medicine, Cairo University, Kasr A Ainy Street, Cairo 11562, Egypt
Objective: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%).
Materials and methods: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally.
Results: We found decreased Tmax, increased Cmax, AUC0–6, AUC0–∞ and ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan.
Conclusion: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.
Keywords: zolmitriptan, Zol, intranasal delivery, brain targeting, spanlastics, SLs, pharmacokinetics, pharmacodynamics, migraine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]